You are here

Acceleron

Sotatercept- the breakthrough PAH has been waiting for?

Sotatercept- the breakthrough PAH has been waiting for?

Clinical Trials Arena

Flag link:

Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy

Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy

Fierce Biotech

clinical trials

pulmonary arterial hypertension

Flag link:

Merck cuts 170 jobs at Acceleron right on heels of $11.5B buyout

Merck cuts 170 jobs at Acceleron right on heels of $11.5B buyout

Fierce Pharma

Flag link:

Is Merck's Planned Acquisition of Acceleron in Trouble?

Is Merck's Planned Acquisition of Acceleron in Trouble?

Motley Fool

Flag link:

Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout

Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout

Fierce Pharma

Bristol Myers Squibb

Aurinia Pharmaceuticals

Flag link:

Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report

Bristol Myers pledges to sell its Acceleron shares as activist investors circle Merck's $11.5B buyout — report

Endpoints

Bristol Myers Squibb

Flag link:

Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention

Report: Multiple Suitors - Including BMS - Vied for Acceleron’s Attention

BioSpace

Bristol Myers Squibb

Flag link:

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Fierce Pharma

Flag link:

Is an Acquisition of Acceleron a Smart Move for Merck?

Is an Acquisition of Acceleron a Smart Move for Merck?

Motley Fool

Flag link:

Biopharma needs a biggie to avoid a down deal year

Biopharma needs a biggie to avoid a down deal year

EP Vantage

Flag link:

Trouble builds for Merck's $11.5B Acceleron buy as activist investor behind Gilead's Immunomedics deal says too early, too cheap

Trouble builds for Merck's $11.5B Acceleron buy as activist investor behind Gilead's Immunomedics deal says too early, too cheap

Fierce Pharma

Flag link:

Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug

Merck Strikes with $11 Billion Deal for Acceleron and Phase III PAH Drug

BioSpace

Flag link:

Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report

Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report

Endpoints

Flag link:

Rumor mill says Acceleron is speeding towards $11bn sale

Rumor mill says Acceleron is speeding towards $11bn sale

Pharmaforum

Flag link:

Acceleron, under threat of fines, reports out a negative study

Acceleron, under threat of fines, reports out a negative study

RAPS.org

clinical trials

Flag link:

Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign

Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign

Endpoints

Flag link:

The "Rare Disease Company Coalition" Launches to Share the Unique Challenges and Promise of Rare Disease Therapy Development to Support Continued Progress and Patient Access

The "Rare Disease Company Coalition" Launches to Share the Unique Challenges and Promise of Rare Disease Therapy Development to Support Continued Progress and Patient Access

Yahoo/Businesswire

Rare Disease Company Coalition

drug development

Aeglea BioTherapeutics

Agios Pharmaceuticals

Harmony Biosciences

Orchard Therapeutics

Sarepta Therapeutics

Taysha Gene Therapies

Flag link:

FDA threatens drugmaker with fines for failing to report trial results

FDA threatens drugmaker with fines for failing to report trial results

RAPS.org

clinical trials

Flag link:

Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status

Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status

Endpoints

breakthrough therapy

Flag link:

Pages